| Tau PTM profiles identify patient heterogeneity and stages of Alzheimer’s disease H Wesseling, W Mair, M Kumar, CN Schlaffner, S Tang, P Beerepoot, ... Cell 183 (6), 1699-1713. e13, 2020 | 413 | 2020 |
| Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease S Dujardin, C Commins, A Lathuiliere, P Beerepoot, AR Fernandes, ... Nature medicine 26 (8), 1256-1263, 2020 | 315 | 2020 |
| Pharmacological chaperones of the dopamine transporter rescue dopamine transporter deficiency syndrome mutations in heterologous cells P Beerepoot, VM Lam, A Salahpour Journal of Biological Chemistry 291 (42), 22053-22062, 2016 | 43 | 2016 |
| Pharmacological chaperone approaches for rescuing GPCR mutants: Current state, challenges, and screening strategies P Beerepoot, R Nazari, A Salahpour Pharmacological research 117, 242-251, 2017 | 31 | 2017 |
| A novel assay for measurement of membrane‐protein surface expression using a β‐lactamase reporter VM Lam, P Beerepoot, S Angers, A Salahpour Traffic 14 (7), 778-784, 2013 | 30 | 2013 |
| Sustained N‐methyl‐d‐aspartate receptor hypofunction remodels the dopamine system and impairs phasic signaling MJ Ferris, M Milenkovic, S Liu, CA Mielnik, P Beerepoot, CE John, ... European Journal of Neuroscience 40 (1), 2255-2263, 2014 | 25 | 2014 |
| Effects of salvinorin A on locomotor sensitization to D2/D3 dopamine agonist quinpirole P Beerepoot, V Lam, A Luu, B Tsoi, D Siebert, H Szechtman Neuroscience letters 446 (2-3), 101-104, 2008 | 20 | 2008 |
| N-terminal tagging of the dopamine transporter impairs protein expression and trafficking in vivo LM Vecchio, MK Bermejo, P Beerepoot, AJ Ramsey, A Salahpour Molecular and Cellular Neuroscience 61, 123-132, 2014 | 15 | 2014 |
| Measurement of G protein-coupled receptor surface expression P Beerepoot, VM Lam, A Salahpour Journal of Receptors and Signal Transduction 33 (3), 162-165, 2013 | 10 | 2013 |
| Author Correction: Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease S Dujardin, C Commins, A Lathuiliere, P Beerepoot, AR Fernandes, ... Nature medicine 27 (2), 356-356, 2021 | 9 | 2021 |
| Behavioral effects of a potential novel TAAR1 antagonist VM Lam, CA Mielnik, C Baimel, P Beerepoot, S Espinoza, I Sukhanov, ... Frontiers in pharmacology 9, 953, 2018 | 9 | 2018 |
| Structure-activity relationships of dopamine transporter pharmacological chaperones C Sutton, EQ Williams, H Homsi, P Beerepoot, R Nazari, D Han, ... Frontiers in Cellular Neuroscience 16, 832536, 2022 | 6 | 2022 |
| A β-lactamase based assay to measure surface expression of membrane proteins P Beerepoot, VM Lam, A Salahpour Membrane Trafficking: Second Edition, 107-114, 2015 | 4 | 2015 |
| Alzheimer proteopathic tau seeds are biochemically a forme fruste of mature paired helical filaments M Kumar, N Quittot, S Dujardin, CN Schlaffner, A Viode, A Wiedmer, ... Brain 147 (2), 637-648, 2024 | 1 | 2024 |
| Discovery of a HeliconTM peptide inhibitor of the beta-catenin-TCF interaction with in vivo activity BH White, Y Si, S Cappucci, Z Li, JD Ramirez, CM Ponthier, E Visness, ... Cancer Research 83 (7_Supplement), 3094-3094, 2023 | | 2023 |
| Anti-tumor activity of Helicon inhibitors of Β-catenin-TCF interaction in patient-derived xenograft models YG Si, M Choi, X Han, B White, Z Wu, E Visness, P Beerepoot, E Jaensch, ... Cancer Research 83 (7_Supplement), 4972-4972, 2023 | | 2023 |
| Development of a novel and direct peptide Helicon࣪ inhibitor of β-catenin-TCF interaction with in vivo validation of transcriptional modulation and anti-tumor activity Y Si, B White, S Cappucci, J Ramirez, C Ponthier, E Visness, K Ling, P Du, ... Cancer Research 82 (12_Supplement), 345-345, 2022 | | 2022 |
| O5‐04‐04: ACCUMULATION OF MODIFICATIONS IN THE TAU CORE REGION DURING THE TAU AGGREGATION PROCESS IN ALZHEIMER'S DISEASE P Beerepoot, H Wesseling, W Mair, M Svrdlikova, L Cheng, H Steen, ... Alzheimer's & Dementia 15, P1623-P1624, 2019 | | 2019 |
| Pharmacological Chaperones of the Dopamine Transporter: A Strategy for Increasing Function of Wild Type and Mutant Transporter PC Beerepoot University of Toronto (Canada), 2017 | | 2017 |
| Pharmacological chaperones of the dopamine transporter P Beerepoot, VM Lam, A Salahpour | | 2016 |
